4basebio PLC (AIM:4BB)
London · Delayed Price · Currency is GBP · Price in GBX 575.00
-15.00 (-2.54%)
Feb 12, 2026, 4:14 PM GMT
4basebio Market Cap
4basebio has a market cap or net worth of 91.32 million as of February 12, 2026. Its market cap has decreased by -40.57% in one year.
Market Cap
91.32M
Enterprise Value
80.64M
Revenue
1.78M
Ranking
n/a
PE Ratio
n/a
Stock Price
575.00
Market Cap Chart
Since February 17, 2021, 4basebio's market cap has increased from 41.57M to 91.32M, an increase of 119.66%. That is a compound annual growth rate of 17.10%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 11, 2026 | 91.32M | -4.07% |
| Dec 31, 2025 | 95.19M | -38.57% |
| Dec 31, 2024 | 154.94M | 84.96% |
| Dec 29, 2023 | 83.77M | -4.21% |
| Dec 30, 2022 | 87.45M | 15.45% |
| Dec 31, 2021 | 75.75M | 82.22% |
| Feb 17, 2021 | 41.57M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Avacta Group | 260.26M |
| Scancell Holdings | 128.68M |
| Bioventix | 92.74M |
| Faron Pharmaceuticals Oy | 77.58M |
| Hemogenyx Pharmaceuticals | 57.51M |
| SkinBioTherapeutics | 51.13M |
| hVIVO | 48.31M |
| Ondine Biomedical | 41.09M |